TICKERNERD
Menu
XFORXFORHealthcare · Biotechnology

XFOR Stock Forecast: X4 Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$3.36
+0.30% on the day

The 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +257.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$322.2M
Ticker Nerd rank
61/ 100
Median analyst target
$12
Analysts covering
5
Revenue$8.8M+346.3% y/y
Operating income−$16.4M
Net income−$16.2M
Free cash flow−$25.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.0%
1M
+15.9%
YTD
−16.0%
1Y
−10.2%
From 52W high
−28.1%
From 52W low
+37.1%
$2.45
$4.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XFOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores X4 Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
61/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Growth
78
Momentum
63
Size
59
Quality
49
Volatility
39
Accruals
36
Value
36
Issuance
29

Revisions (89): Analysts have, on balance, been raising their forecasts.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XFOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XFOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26XFORHigh $13Median $12Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $10Median $12High $13

The green dot is the last close — the median target sits +257.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 July 2026Wells FargoInitiatesOverweight$11
2 June 2026Leerink PartnersInitiatesOutperform—
9 Mar 2026GuggenheimInitiatesBuy—
5 Dec 2025StifelMaintainsBuy—
10 Nov 2025HC Wainwright & Co.MaintainsBuy—
29 Aug 2025StifelMaintainsBuy—
13 Aug 2025HC Wainwright & Co.MaintainsBuy—
2 May 2025HC Wainwright & Co.MaintainsBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.MaintainsBuy—
14 Nov 2024StifelMaintainsBuy—
28 June 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024Cantor FitzgeraldReiteratesOverweight—
30 Apr 2024HC Wainwright & Co.MaintainsBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2023B. Riley SecuritiesDowngradeNeutral—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XFOR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XFOR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, X4 Pharmaceuticals, Inc. returned −10.2% against +13.1% for the S&P 500, dividends included.

XFOR vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26XFORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XFOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

X4 Pharmaceuticals, Inc. (XFOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
162.5×

Cheaper than 4% of US stocks

Price / sales
20.3×

Cheaper than 9% of US stocks

Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
−2.4×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
346.3%

Higher than 97% of US stocks

Earnings growth (YoY)
—
Gross margin
81.6%

Higher than 92% of US stocks

Operating margin
−186.1%

Higher than 11% of US stocks

Net margin
83.6%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−113.1%

Higher than 12% of US stocks

Return on assets
−28.1%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

X4 Pharmaceuticals, Inc. (XFOR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • X4 Pharmaceuticals, Inc. has a market value of $322.2M and an enterprise value of $191.5M.

  • Revenue in the twelve months to 30 June 2026: $15.8M. The latest quarter grew 346.3% year on year.

  • Net income over the same four quarters: −$90.1M, a −568.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$88.7M.

  • Shares outstanding: 96.1M.

  • Trailing P/E: 162.5×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • X4 Pharmaceuticals, Inc. employs 45 people — $352K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

XFOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XFORX4 Pharmaceuticals, Inc.$322.2M61
SCTXScribe Therapeutics, Inc.$330.9M2
ALECAlector, Inc.$333.6M55
PRLDPrelude Therapeutics, Inc.$329.7M91
ENTAEnanta Pharmaceuticals, Inc.$336.4M91
TTRXTurn Therapeutics, Inc.$327.4M22
AVIRAtea Pharmaceuticals, Inc.$342.5M74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own X4 Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XFOR news & analysis

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

GlobeNewsWire · 29 Oct 2026positive

X4 Pharmaceuticals highlighted clinical progress for mavorixafor in primary chronic neutropenia during a virtual investor day. The company estimated a U.S. base-case market of 15,000 patients, with potential to expand to approximately 30,000.

Why it matters — The update outlines the patient market opportunity XFOR investors may track alongside mavorixafor’s clinical progress.

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

MarketBeat · 29 Oct 2026neutral

X4 Pharmaceuticals said it expects to complete enrollment in the pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia by the end of Q4 2026. Top-line data are anticipated in Q1 2028.

Why it matters — The enrollment and data timeline provides XFOR watchers with an update on the anticipated progress of the mavorixafor trial.

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

GlobeNewsWire · 8 Oct 2026positive

X4 Pharmaceuticals entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures, replacing its prior loan agreement. The company also expects to complete enrollment in the Phase 3 4WARD trial by year-end 2026, with topline data in the first half of 2028.

Why it matters — The new facility provides access to funding for corporate and commercial activities, while the stated trial timeline gives XFOR watchers an update on the 4WARD program.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Oct 2026neutral

X4 Pharmaceuticals announced that, effective September 30, 2026, it issued inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase an aggregate of 80,000 shares of common stock, granted under Nasdaq Listing Rule 5635(c)(4) and approved by the Compensation Committee.

Why it matters — The news signals a potential increase in outstanding shares as X4 recruits new employees through equity-based inducement grants, which XFOR watchers may monitor for dilution and hiring activity.

FAQ

Frequently asked questions about XFOR stock

What is the XFOR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XFOR stock a buy right now?

Of the 5 analysts covering X4 Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks X4 Pharmaceuticals, Inc. 61 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XFOR?

As at 28 Oct 2026, X4 Pharmaceuticals, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will XFOR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +257.1% from the last close, and Ticker Nerd's factor model ranks X4 Pharmaceuticals, Inc. 61 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XFOR stock forecast for 2030?

No analyst covering X4 Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XFOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.

How has XFOR stock performed over the past year?

X4 Pharmaceuticals, Inc. returned -10.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does X4 Pharmaceuticals, Inc. do?

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders.

What is the latest news on XFOR?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day". X4 Pharmaceuticals highlighted clinical progress for mavorixafor in primary chronic neutropenia during a virtual investor day. The company estimated a U.S. base-case market of 15,000 patients, with potential to expand to approximately 30,000.

Company

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency. X4 Pharmaceuticals markets XOLREMDI in the United States and continues to evaluate mavorixafor in additional indications through clinical development programs. Its portfolio and commercial activity place it at the intersection of immunology, hematology, and rare-disease care, serving patients with significant unmet medical needs. Based in Boston, Massachusetts, X4 Pharmaceuticals plays a specialized role in the biotechnology market by focusing on treatments for underserved patient populations.

CEO Dr. Paula Ragan Ph.D. · 45 employees · United States · https://www.x4pharma.com